Market Place
Sourcing Support
Galecto Reports Q3 2024 Financial Results
01 Nov 2024 //
GLOBENEWSWIRE
Galecto Strengthens Board of Directors with Appointment of Dr. Amy
15 Oct 2024 //
GLOBENEWSWIRE
Galecto buys leukemia drug, drops bone cancer asset in pivot
08 Oct 2024 //
FIERCE BIOTECH
Galecto Announces Reverse Stock Split
28 Aug 2024 //
GLOBENEWSWIRE
Galecto: First Patient Dosed In GB1211-Pembrolizumab Combo Trial
01 May 2024 //
GLOBENEWSWIRE
Galecto posts myelofibrosis data as search for savior continues
21 Dec 2023 //
FIERCE BIOTECH
Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow
21 Dec 2023 //
GLOBENEWSWIRE
Galecto Presents Updated Clinical Data at ESMO Congress 2023
23 Oct 2023 //
GLOBENEWSWIRE
Galecto lays off 70% in wake of fibrosis drug`s phase 2 fail
27 Sep 2023 //
FIERCE BIOTECH
Galecto Announces Plans to Explore Strategic Alternatives
26 Sep 2023 //
GLOBENEWSWIRE
Galecto to Present at Investor Conferences in September
31 Aug 2023 //
GLOBENEWSWIRE
Galecto Drops Idiopathic Pulmonary Fibrosis Hopeful After Phase II Flop
16 Aug 2023 //
BIOSPACE
Galecto Reports Second Quarter Operating and Financial Results
31 Jul 2023 //
GLOBENEWSWIRE
Galecto Set to Join Russell Microcap® Index
20 Jun 2023 //
GLOBENEWSWIRE
Galecto to Present at the Upcoming Jefferies Healthcare Conference
30 May 2023 //
GLOBENEWSWIRE
Galecto Completes Dosing in 52-Week Phase 2b GALACTIC-1 Trial of GB0139
23 May 2023 //
GLOBENEWSWIRE
Galecto to Present Poster at Upcoming ATS 2023 International Conference
17 May 2023 //
GLOBENEWSWIRE
Galecto to Present Two Posters at AACR Annual Meeting 2023
13 Apr 2023 //
GLOBENEWSWIRE
Galecto Reports Operating and Financial Results for Year Ended December 31, 2022
09 Mar 2023 //
GLOBENEWSWIRE
Galecto to Participate in Oppenheimer`s 33rd Annual Healthcare Conference
02 Mar 2023 //
GLOBENEWSWIRE
Galecto to Participate in SVB Securities Global Biopharma Conference
01 Feb 2023 //
GLOBENEWSWIRE
Galecto Announces Upcoming Presentation Detailing Results from MYLOX-1 Trial
07 Dec 2022 //
GLOBENEWSWIRE
Galecto Presents +ve Clinical Data at AASLD Showing Statistically Significant
08 Nov 2022 //
GLOBENEWSWIRE
Galecto travels deeper into liver disease with GULLIVER-2 data
08 Nov 2022 //
FIERCEBIOTECH
Galecto to Participate in Jefferies London Healthcare Conference
03 Nov 2022 //
GLOBENEWSWIRE
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial
31 Oct 2022 //
GLOBENEWSWIRE
Galecto’s Galectin-3 Inhibitor GB1211 to be Studied with Pembrolizumab
19 Oct 2022 //
GLOBENEWSWIRE
Galecto to Host Virtual Investor Event & Webcast to Review Topline GULLIVER-2
17 Oct 2022 //
GLOBENEWSWIRE
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients Myelofibrosis
29 Sep 2022 //
GLOBENEWSWIRE
Galecto links blood cancer prospect to reduced fibrosis
29 Sep 2022 //
FIERCEBIOTECH
Galecto to Participate at H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Galecto Announces Publication Supporting the Predictive Role of Galectin-3
29 Aug 2022 //
GLOBENEWSWIRE
Galecto Reports Second Quarter Operating and Financial Results
29 Jul 2022 //
GLOBENEWSWIRE
Galecto Begins Enrollment in Trial of GB1211 + Atezolizumab for 1L NSCLC
16 Jun 2022 //
GLOBENEWSWIRE
Galecto to Participate at Jefferies Healthcare Conference
31 May 2022 //
GLOBENEWSWIRE
Galecto to Present New Data on Oral Galectin-3 Inhibitor GB1211 at the 2022 ASCO
26 May 2022 //
GLOBENEWSWIRE
Galecto to Participate at Upcoming Investor Conferences
02 May 2022 //
GLOBENEWSWIRE
Galecto Reports First Quarter Operating and Financial Results
29 Apr 2022 //
GLOBENEWSWIRE
Galecto concludes enrolment in Phase IIb IPF treatment trial
27 Apr 2022 //
CLINICALTRIALSARENA
Galecto Completes Enrollment in Global Phase 2b GALACTIC-1 Trial of GB0139
26 Apr 2022 //
GLOBENEWSWIRE
Galecto Completes Enrollment in Phase 1b/2a GULLIVER-2 Trial of GB1211
29 Mar 2022 //
GLOBENEWSWIRE
Galecto Reports Financial Results for the Year Ended December 31, 2021
17 Feb 2022 //
GLOBENEWSWIRE
Galecto to Participate at Upcoming Investor Conferences
07 Feb 2022 //
GLOBENEWSWIRE
Galecto Publishes Results Showing Safety and Efficacy of GB0139 in COVID-19
27 Jan 2022 //
GLOBENEWSWIRE
HistoIndex and Galecto to Collaborate on Galecto`s Ph 2a MYLOX-1 Clinical Trial
20 Oct 2021 //
PRNEWSWIRE
Galecto to Present at 2021 Cantor Virtual Global Healthcare Conference
15 Sep 2021 //
GLOBENEWSWIRE
Galecto Doses First Patient Treated in Phase 2 Trial of GB1211
13 Sep 2021 //
GLOBENEWSWIRE
Galecto Announces Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor
18 Aug 2021 //
GLOBENEWSWIRE
Galecto Reports Second Quarter Operating and Financial Results
05 Aug 2021 //
GLOBENEWSWIRE
Galecto Resumes Recruitment in Phase 2b Global GALACTIC-1 Trial
13 Jul 2021 //
GLOBENEWSWIRE
Galecto’s GB0139 Shows Favorable Safety and Tolerability Profile
22 Jun 2021 //
GLOBENEWSWIRE
UPDATE: Galecto Hosting Expert Perspective Panel on the Evolving
23 Mar 2021 //
GLOBENEWSWIRE
Galecto Announces Outcome of Data Safety Monitoring Board Interim Review
15 Mar 2021 //
GLOBENEWSWIRE
Galecto Successful Completion of $64M equity Financing
27 Sep 2020 //
BIOSPACE
Galecto bags $64M to push lung fibrosis med toward EU nod
26 Sep 2020 //
FIERCE BIOTECH
Galecto Raises USD 64m to Accelerate Development of Clinical Pipeline
25 Sep 2020 //
PRNEWSWIRE
Galecto’s Oral Galectin-3 Inhibitor GB1211 Well Tolerated in Phase 1 Data
15 Sep 2020 //
GLOBENEWSWIRE
Galecto, Inc. Receives U.S. and EU Orphan Drug Designations for GB0139
27 Aug 2020 //
GLOBENEWSWIRE
Galecto Advances Phase 2b Study of GB0139 in Idiopathic Pulmonary Fibrosis
06 May 2020 //
GLOBENEWSWIRE
Galecto Presents GB0139 Preclinical and Clinical Data on Anti-Fibrotic Activity
04 May 2020 //
GLOBENEWSWIRE
